1TGTX Stock Overview

A commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. More details

1TGTX fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	6/6
Past Performance	1/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 74.5% below our estimate of its fair value

Earnings are forecast to grow 38.42% per year

Risk Analysis

Shares are highly illiquid

High level of non-cash earnings

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

TG Therapeutics, Inc. Competitors

Philogen

BIT:PHIL

€906.5m

Telix Pharmaceuticals

ASX:TLX

AU$8.6b

Protagonist Therapeutics

NasdaqGM:PTGX

US$2.8b

PharmaEssentia

TWSE:6446

NT$169.2b

Price History & Performance

Summary of share price highs, lows and changes for TG Therapeutics
Historical stock prices
Current Share Price	US$29.77
52 Week High	US$0
52 Week Low	US$0
Beta	2.21
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-15.78%

Recent updates

Shareholder Returns

	1TGTX	IT Biotechs	IT Market
7D	-4.6%	-6.8%	3.2%
1Y	n/a	-1.1%	13.2%

Return vs Industry: Insufficient data to determine how 1TGTX performed against the Italian Biotechs industry.

Return vs Market: Insufficient data to determine how 1TGTX performed against the Italian Market.

Price Volatility

Is 1TGTX's price volatile compared to industry and market?
1TGTX volatility
1TGTX Average Weekly Movement	n/a
Biotechs Industry Average Movement	8.5%
Market Average Movement	5.5%
10% most volatile stocks in IT Market	8.8%
10% least volatile stocks in IT Market	3.4%

Stable Share Price: 1TGTX's share price has been volatile over the past 3 months compared to the Italian market.

Volatility Over Time: Insufficient data to determine 1TGTX's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1993	352	Mike Weiss	www.tgtherapeutics.com

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody.

TG Therapeutics, Inc. Fundamentals Summary

How do TG Therapeutics's earnings and revenue compare to its market cap?
1TGTX fundamental statistics
Market cap	€4.56b
Earnings (TTM)	€34.98m
Revenue (TTM)	€345.27m

124.3x

P/E Ratio

12.6x

P/S Ratio

Is 1TGTX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1TGTX income statement (TTM)
Revenue	US$386.39m
Cost of Revenue	US$48.59m
Gross Profit	US$337.80m
Other Expenses	US$298.65m
Earnings	US$39.15m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	0.27
Gross Margin	87.43%
Net Profit Margin	10.13%
Debt/Equity Ratio	103.5%

How did 1TGTX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/13 13:18
End of Day Share Price	2025/05/13 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

TG Therapeutics, Inc. is covered by 19 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Alec Stranahan	BofA Global Research
Jonathan Aschoff	Brean Capital
Mayank Mamtani	B. Riley Securities, Inc.

TG Therapeutics BIT:1TGTX Stock Report